{"id":"W2157049259","doi":"10.3747/co.21.1661","title":"Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Cetuximab; Medicine; Vemurafenib; KRAS; Colorectal cancer; Trametinib; Cancer research; Dabrafenib; Targeted therapy; Oncology; Epidermal growth factor receptor; Kinase; Internal medicine; Refractory (planetary science); EGFR inhibitors; Cancer; Melanoma; MAPK/ERK pathway; Metastatic melanoma; Biology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002353507,0.0003944626,0.0009458024,0.0003230731,0.0002635952,0.0003742496,0.0003428936,0.0003697142,0.0008702028],"category_scores_gemma":[0.000348211,0.000174392,0.0003348323,0.0002158055,0.0002683086,0.0002131835,0.0002675392,0.0008638136,0.0002638927],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004838083,"about_ca_system_score_gemma":0.000299937,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001280394,"about_ca_topic_score_gemma":0.003320008,"domain_scores_codex":[0.9998696,0.00003460548,0.00001089028,0.00002180023,0.00002446211,0.00003871012],"domain_scores_gemma":[0.999853,0.00003624734,0.00002047705,0.0000170687,0.000009574674,0.00006363911],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.02683231,0.009687028,0.01248918,0.0003751468,0.000407416,0.01218827,0.0004364626,0.01208831,0.6485126,0.0006441057,0.002345207,0.2739939],"study_design_scores_gemma":[0.0172637,0.4680198,0.126972,0.0000943302,0.001259948,0.03598937,0.0003156394,0.03429475,0.2810188,0.0008016346,0.0337847,0.0001854473],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957417,0.001184145,0.0005177893,0.0001954459,0.00004229416,0.0001224206,0.00005703271,0.0000380073,0.002101099],"genre_scores_gemma":[0.998198,0.0004267037,0.0004739339,0.0000727758,0.0000431903,0.00002804323,0.0001505235,0.000007597013,0.0005992189],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001280394,"threshold_uncertainty_score":0.003510296,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1687028635476653,"score_gpt":0.4394991136432984,"score_spread":0.270796250095633,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}